Advance your discovery efforts more quickly by screening a large number of early-stage test agents against a subset of the ~300 available OncoPanel® cell lines, in a panel customized to meet your program’s needs. Survey gene family effects for drug repositioning efforts with gene-specific subpanels, focus on tissue lineage-specific cancer subpanels, or screen against our whole collection for a broader evaluation. Whatever your need, make empowered decisions with insights on efficacy, patient stratification, and the influence of genomic aberrations on the biological response to your test agent or candidate.
The ability to design gene family expression and tissue-focused panels for use with OncoPanel standard 2D, 3D spheroid, and combination assays means focused candidate assessment is possible, which can then be followed by broader, more thorough evaluation for IND submission.
Profile your small molecule, biologic, nucleotide, nanobody, or other innovative therapeutic modality in human tumor cell line panels curated for specific target pathways. These include enzymatic, epigenetic, G protein-coupled receptor (GPCR), growth factor receptor, ion channels, kinase, nuclear hormone receptor, transcription factor targets, protein degraders, molecular glues, antibody-drug conjugates (ADCs), and more. Tissue lineage-specific subpanels include bladder, bone, breast, colorectal, female genitourinary, hematopologic, kidney, lung, pancreas, prostate, and soft tissue, as well as certain tissue subtypes.
With gene-specific and tissue lineage-specific cancer subpanels, you can:
- Extend results from target-based in vitro assays to a functional cellular assessment
- Determine antiproliferative or cytotoxic activities
- Evaluate test agents for efficacy and selectivity
- Identify potential genomic biomarkers for both sensitivity and resistance
- Rank-order and prioritize candidates for further development
Genomic aberrations represented in OncoPanel cell line subpanels are the same as those included in OncoPanel full-panel assays: mutations, amplifications, deletions, and overexpression. Singleplex assays provide data on cell proliferation; multiplexed assays include readouts for the induction of apoptosis and effects on the cell cycle (mitosis) (see Features).
Example Gene-specific Human Tumor Cell Line Panel Options
| Target Class | Gene Examples | Example Datasets |
|---|---|---|
| Enzymes | KRAS, PARP1, TNKS | sotorasib, olaparib, talazoparib |
| Epigenetic Targets | BRD4, EZH2, HDAC1 | panobinostat, vorinostat |
| G Protein-coupled Receptors (GPCR) | CNR1/CNR2, DRD2, SMO | vismodegib |
| Growth Factor Receptors | EGFR, IGFR1, MET | afatinib, cetuximab, osimertinib |
| Ion Channels | ABCC9, KCNH2, KCNK2 | |
| Kinases | BRAF, FLT3, PIK3CA | vemurafenib, sunitinib, idelalisib |
| Nuclear Hormone Receptors | AhR, AR, ER | fulvestrant |
| Protein Degraders | MDM2 | nutlin-3, nutlin-3a |
| Transcription Factors | ESR1, MYC, STAT3 |
*18,000+ genes available for creation of custom cell panels to inform on test agent impact.
Identify Mechanisms of Sensitivity and Resistance with Gene-specific and Full OncoPanel Profiling
Figure 1. Identification of mutations associated with sensitivity or resistance to nutlin-3 treatment of OncoPanel human tumor cell lines. This figure shows data from OncoPanel full-panel analysis; data from nutlin-3 and nutlin-3a treatment are included in the Protein Degraders gene-specific panel. Nutlin-3 and nutlin-3a are MDM2 (human homolog of murine double minute-2; HDM2) antagonists with antineoplastic activity through their ability to stabilize p53.
